Oncolytics Biotech® Appoints John McAdory as EVP of Strategy and Operations and Yujun Wu to Lead Biostatistics

Core Viewpoint - Oncolytics Biotech Inc. has appointed John McAdory as Executive Vice President of Strategy and Operations and Yujun Wu as Vice President, Head of Biostatistics to enhance its operational, clinical, and regulatory capabilities as it advances registration-directed development programs in gastrointestinal cancers [1][4]. Group 1: Appointments and Roles - John McAdory will oversee clinical development execution, operational strategy, and regulatory readiness across the Company's portfolio, bringing extensive experience in leading late-stage oncology programs [2][3]. - Yujun Wu will lead Biostatistics, contributing expertise in statistical strategy, regulatory interactions, and late-stage trial design, having previously supported multiple clinical programs through late-stage development [3][4]. Group 2: Strategic Focus - The appointments support Oncolytics' strategic focus on advancing pelareorep through efficient regulatory pathways, prioritizing indications with high unmet medical need, including squamous cell anal cancer, pancreatic cancer, and KRAS-mutant colorectal cancer [4][10]. - The Company is actively pursuing accelerated approval strategies and pivotal trials, emphasizing the importance of high-quality statistical leadership at this critical time [4][10]. Group 3: Inducement Awards - In connection with their appointments, the Company granted inducement equity awards to Mr. McAdory and Mr. Wu, including stock options with an exercise price of US$0.97 [5][6]. - Mr. McAdory received an award of 300,000 restricted share units that will vest upon a material transaction, while he also received 500,000 stock options [7][8].